ACTRN12605000695606
Completed
Not Applicable
An evaluation of a decision aid for women aged 70 considering whether to stop or continue having mammography screening.
Screening and Test Evaluation Program (University of Sydney)0 sites670 target enrollmentOctober 28, 2005
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Screening and Test Evaluation Program (University of Sydney)
- Enrollment
- 670
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Women who are due their FIRST screening mammogram, and who have previously participated in screening mammography at BreastScreen NSW.
Exclusion Criteria
- •Women not sufficiently proficient in English to complete the CATI and read the decision aid / standard care information and postal questionnaire.Women with a personal history of breast cancer (invasive or pre\-invasive).
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Australian Screening Mammography Decision Aid Trial (ASMDAT)Breast NeoplasmsNCT00247442University of Sydney670
Terminated
Not Applicable
A Breast Cancer Treatment Decision Aid for Women Aged 70 and OlderBreast CancerEstrogen Receptor Positive Breast CancerNode-negative Breast CancerHuman Epidermal Growth Factor 2 Negative Carcinoma of BreastNCT02823262Beth Israel Deaconess Medical Center65
Completed
Not Applicable
Evaluation of a decision aid for women with a breech-presenting babyBreech pregnancy at termPregnancy and ChildbirthBreech pregnancyISRCTN14570598Australian National Health and Medical Research Council (Australia)184
Active, not recruiting
Not Applicable
Identifying Decision Making Needs for Older Adult Women With Stage I-III Breast Cancer Considering Neoadjuvant or Adjuvant ChemotherapyNCT05049746M.D. Anderson Cancer Center95
Completed
Not Applicable
Trial in adults aged 65 years or older to evaluate the immunogenicity of influenza vaccine.nonJPRN-UMIN000003720influenza vaccine Research Group60